Baseline data
| Trial | Treatment | N | Female (%) | RF positive (%) | Age | Duration of RA | SDAI | HAQ | TSS |
|---|---|---|---|---|---|---|---|---|---|
| BELIRA | Glucocorticoids | 77 | 89.6 | 68.8 | 53.8±12.1 | 10±8 | 25.9±13.7 | 1.14±0.71 | 38.1±45.4 |
| ASPIRE | Infliximab | 452 | 70.1 | 71.1 | 49.5±12.8 | 0.8±0.7 | 37.9±12.4 | 1.5±0.67 | 11.1±15.1 |
| MTX | 175 | 74.0 | 74.2 | 49.2±12.9 | 0.8±0.7 | 38.0±11.5 | 1.53±0.59 | 12.0±17.0 | |
| PREMIER | Adalimumab | 139 | 74.1 | 81.9 | 52.7±13.3 | 0.7±0.7 | 48.1±13.6 | 1.59±0.59 | 18.9±19.1 |
| Adalimumab+MTX | 174 | 72.8 | 80.1 | 51.6±14.5 | 0.7±0.8 | 48.4±15.0 | 1.47±0.63 | 19.0±21.5 | |
| MTX | 143 | 73.1 | 75.9 | 52.6±13.2 | 0.8±0.9 | 49.4±14.1 | 1.5±0.66 | 23.0±24.0 | |
| ERA | Etanercept | 139 | 72.9 | 74.7 | 50.7±13.3 | 1.0±1.0 | 44.8±15.5 | 1.46±0.66 | 10.7±14.0 |
| MTX | 145 | 67.8 | 78.2 | 48.6±12.9 | 1.1±0.9 | 43.8±15.9 | 1.44±0.59 | 11.5±12.4 | |
| TEMPO | Etanercept | 151 | 76.6 | 68.8 | 53.0±13.9 | 6.3±5.1 | 36.1±14.2 | 1.39±0.68 | 26.4±48.4 |
| Etanercept+MTX | 169 | 73.7 | 66.2 | 52.4±12.5 | 6.8±5.4 | 34.2±15.6 | 1.38±0.69 | 33.0±45.3 | |
| MTX | 136 | 78.4 | 65.3 | 52.8±12.8 | 6.8±5.5 | 41.5±16.7 | 1.49±0.74 | 33.9±48.5 | |
| ATTRACT | Infliximab | 190 | 76.7 | 78.2 | 52.9±11.6 | 10.2±8.1 | 46.6±14.8 | 1.64±0.61 | 66.9±62.2 |
| Placebo | 42 | 80.9 | 77.6 | 51.4±12.1 | 10.5±8.4 | 43.8±13.6 | 1.60±0.63 | 70.1±68.1 | |
| DE019 | Adalimumab+MTX | 322 | 73.8 | 84.2 | 55.7±12.2 | 10.7±9.4 | 40.6±12.6 | 1.45±0.62 | 66.0±53.4 |
| LEF | Leflunomide | 294 | 72.7 | 72.6 | 57.9±10.2 | 4.0±4.2 | 49.6±13.6 | 1.5±0.69 | 27.8±35.6 |
| MTX | 272 | 72.3 | 72.6 | 57.1±11.0 | 3.8±3.6 | 50.6±13.2 | 1.49±0.67 | 24.2±34.8 | |
| Salazopyrine | 35 | 65.2 | 74.6 | 58.4±11.1 | 6.1±8.6 | 47.7±12.5 | 1.33±0.64 | 44.3±55.8 |
ASPIRE, ‘Active-controlled Study of Patents receiving Infliximab for the treatment of RA of Early onset’; ATTRACT, ‘Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy’; BELIRA, ‘BEst LIfe with Rheumatoid Arthritis’; ERA, ‘Early Rheumatoid Arthritis’; HAQ, Health Assessment Questionnaire; LEF, leflunomide; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TEMPO, ‘Trial of Etanercept and Methotrexate with radiographic Patient Outcomes’; TSS, total Sharp score.